Short answer
4D Molecular Therapeutics, Inc. (FDMT) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $3M (up 21664.3% year over year) with net income of −$69M.
Q1 2026 key financials · XBRL
- Revenue
- $3M
- +21664.3% YoY
- Net income
- −$69M
- −43.3% YoY
- Operating margin
- -2416.1%
- EPS (diluted)
- −$1.01
- −17.4% YoY
Source: XBRL data from the 4D Molecular Therapeutics, Inc. (FDMT) Q1 2026 10-Q on SEC EDGAR. USD.
4D Molecular Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $3.047M, up $3.033M YoY from $14K, driven by Otsuka cost sharing and reimbursements
- Net loss $68.760M vs $47.972M YoY, with operating loss $73.620M vs $53.621M
- Wet AMD R&D highest-growth program, direct expenses $42.682M, up 235% YoY
- Cash, equivalents and marketable securities $457.6M; operating cash use $68.125M vs $47.758M YoY
- Outlook: topline 4FRONT-1 data first half 2027; additional funding required, with macroeconomic and financing headwinds
Risk Factors
- No newly triggered risk factor identified; filing presents existing 10-K risks without an explicit “no material changes” statement
- Liquidity risk: $457.6 million in cash, cash equivalents and marketable securities funds planned operations for at least one year
- Financial loss risk: $68.8 million quarterly net loss and $785.1 million accumulated deficit as of March 31, 2026
- Regulatory risk: evolving FDA, EMA and NIH requirements may require additional studies and delay gene-therapy approvals
- Operational risk: no products approved or product revenue, leaving near-term performance dependent on clinical development progress
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other 4D Molecular Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.